Gastrointestinal stromal tumors.

Current treatment options in oncology

Volumn 2, Issue 6, 2001, Pages 485-491

  Blanke, Charles D ^a,b   Eisenberg, Burton L ^a,b   Heinrich, Michael C ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR; TUMOR MARKER; TUMOR PROTEIN;

ABDOMINAL SURGERY; ADJUVANT CHEMOTHERAPY; CONNECTIVE TISSUE TUMOR; DRUG ANTAGONISM; EPIDEMIOLOGY; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOTHERAPY; METASTASIS; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; ENZYME INHIBITORS; EPIDEMIOLOGIC METHODS; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, CONNECTIVE TISSUE; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0035749620     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-001-0070-0     Document Type: Review

References (19)

1. 1. M Miettinen J Lasota 2000 Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis Virchows Arch 438 1 12 10.1007/s004280000338 Thorough review of the biologic features of GISTs. Miettinen M, Lasota J: Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2000, 438:1–12. Thorough review of the biologic features of GISTs.
2. 2. S Suster 1996 Gastrointestinal stromal tumors Semin Diagn Pathol 13 297 313 8946608 1:STN:280:DyaK2s7gt1Sqtg%3D%3D Suster S: Gastrointestinal stromal tumors. Semin Diagn Pathol 1996, 13:297–313.
3. 3. BEC Plaat H Hollema WM Molenaar 2000 Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins J Clin Oncol 18 3211 3220 10986053 1:STN:280:DC%2BD3cvotlentA%3D%3D Comparison of GISTs and standard leiomyosarcomas. Plaat BEC, Hollema H, Molenaar WM, et al.: Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000, 18:3211–3220. Comparison of GISTs and standard leiomyosarcomas.
4. 4. H Hirota K Isozaki Y Moriyama 1998 Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580 9438854 10.1126/science.279.5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D A basic science classic that details the role of activating c-kit mutation in GISTs. Hirota H, Isozaki K, Moriyama Y, et al.: Gain-offunction mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577–580. A basic science classic that details the role of activating c-kit mutation in GISTs.
5. 5. KC Conlon ES Casper MF Brennan 1995 Primary gastrointestinal sarcomas: analysis of prognostic variables Ann Surgical Oncol 2 26 31 10.1007/BF02303698 1:STN:280:DyaK2M7js1SntQ%3D%3D Conlon KC, Casper ES, Brennan MF: Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surgical Oncol 1995, 2:26–31.
6. 6. PC Lindsay N Ordonez JH Raaf 1981 Gastric leiomyosarcoma: clinical and pathological review of fifty patients J Surg Oncol 18 399 421 6172674 10.1002/jso.2930180409 1:STN:280:DyaL387gt1elsg%3D%3D Lindsay PC, Ordonez N, Raaf JH: Gastric leiomyosarcoma: clinical and pathological review of fifty patients. J Surg Oncol 1981, 18:399–421.
7. 7. RP DeMatteo JJ Lewis D Leung 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 231 51 58 10636102 10.1097/00000658-200001000-00008 1:STN:280:DC%2BD3c7gtVSmtQ%3D%3D Excellent single institutional surgical review of confirmed GIST. DeMatteo RP, Lewis JJ, Leung D, et al.: Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000, 231:51–58. Excellent single institutional surgical review of confirmed GIST.
8. 8. EH Ng RE Pollock MF Munsel 1992 Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging Ann Surg 215 68 77 1731651 1:STN:280:DyaK387hslOntw%3D%3D 10.1097/00000658-199201000-00010 Large series with long-term follow up of GIST patients, including presentation with metastatic and locally recurrent disease. Ng EH, Pollock RE, Munsel MF, et al.: Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992, 215:68–77. Large series with long-term follow up of GIST patients, including presentation with metastatic and locally recurrent disease.
9. 9. PC McGrath JP Neifeld WJ Lawrence 1987 Gastrointestinal sarcomas. Analysis of prognostic factors Ann Surg 206 706 710 3689007 10.1097/00000658-198712000-00004 1:STN:280:DyaL1c%2Fns1WlsA%3D%3D McGrath PC, Neifeld JP, Lawrence WJ, et al.: Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 1987, 206:706–710.
10. 10. MH Shiu GH Farr DN Papachristou 1982 Myosarcomas of the stomach: natural history, prognostic factors and management Cancer 49 177 187 7053814 10.1002/1097-0142(19820101)49:1<177::AID-CNCR2820490136>3.0.CO;2-K 1:STN:280:DyaL38%2FptlSltw%3D%3D Shiu MH, Farr GH, Papachristou DN, et al.: Myosarcomas of the stomach: natural history, prognostic factors and management. Cancer 1982, 49:177–187.
11. 11. OE Akwari RR Dozois LH Weiland 1978 Leiomyosarcoma of the small and large bowel Cancer 42 1375 1384 81101 10.1002/1097-0142(197809)42:3<1375::AID-CNCR2820420348>3.0.CO;2-4 1:STN:280:DyaE1M%2Fit1Oqug%3D%3D Akwari OE, Dozois RR, Weiland LH, et al.: Leiomyosarcoma of the small and large bowel. Cancer 1978, 42:1375–1384.
12. 12. J Edmonson R Marks J Buckner 1999 Contrast of D-MAP + sargramostim between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas Proc Am Soc Clin Oncol 18 541a 541a The first major study to separate GISTs from muscle tumors. It carefully details response rates to sarcoma-oriented chemotherapy. Edmonson J, Marks R, Buckner J, et al.: Contrast of D-MAP + sargramostim between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Proc Am Soc Clin Oncol 1999, 18:541a [abstract 2088]. The first major study to separate GISTs from muscle tumors. It carefully details response rates to sarcoma-oriented chemotherapy.
13. 13. CD Blanke Mehren M von H Joensuu 2001 Evaluation of the safety and efficacy of an oral molecularlytargeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit (CD117) Proc Am Soc Clin Oncol 20 1a 1a The largest reported treatment series to feature GIST patients only. Blanke CD, von Mehren M, Joensuu H, et al.: Evaluation of the safety and efficacy of an oral molecularlytargeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors expressing c-kit (CD117). Proc Am Soc Clin Oncol 2001, 20:1a [abstract 1]. The largest reported treatment series to feature GIST patients only.
14. 14. MC Heinrich DJ Griffith BJ Druker 2000 Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor Blood 96 925 32 10910906 1:CAS:528:DC%2BD3cXltlKitLw%3D Detailed description of the effect of STI571 on wild-type and mutated c-Kit. Heinrich MC, Griffith DJ, Druker BJ, et al.: Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96:925–32. Detailed description of the effect of STI571 on wild-type and mutated c-Kit.
15. 15. BJ Druker M Talpaz DJ Resta 2001 Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 11287972 10.1056/NEJM200104053441401 1:CAS:528:DC%2BD3MXivFGnu70%3D Druker BJ, Talpaz M, Resta DJ, et al.: Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031–1037.
16. 16. H Joensuu PJ Roberts M Sarlomo-Rikala 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 1056 11287975 10.1056/NEJM200104053441404 1:STN:280:DC%2BD3M3gvVekuw%3D%3D The first description of an effective systemic therapy in GISTs. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052–1056. The first description of an effective systemic therapy in GISTs.
17. 17. AT Oosterom Van I Judson J Verweij 2001 STI571, an active drug in metastatic gastrointestinal stromal tumors, an EORTC phase I study Proc Am Soc Clin Oncol 20 1a 1a Phase I trial of STI571 in KIT+ GIST and other soft tissue sarcomas. Van Oosterom AT, Judson I, Verweij J, et al.: STI571, an active drug in metastatic gastrointestinal stromal tumors, an EORTC phase I study. Proc Am Soc Clin Oncol 2001, 20:1a [abstract 2]. Phase I trial of STI571 in KIT+ GIST and other soft tissue sarcomas.
18. 18. J Pollock D Morgan J Denobile 2001 Adjuvant radiotherapy for gastrointestinal stromal tumor of the rectum Dig Dis Sci 46 268 272 11281173 10.1023/A:1005581000712 1:STN:280:DC%2BD3M3gvVCkug%3D%3D Pollock J, Morgan D, Denobile J, et al.: Adjuvant radiotherapy for gastrointestinal stromal tumor of the rectum. Dig Dis Sci 2001, 46:268–272.
19. 19. Y Shioyama Y Yakeishi T Watanabe 2001 Long-term control for a retroperitoneal metastasis of malignant gastrointestinal stromal tumor after chemoradiotherapy and immunotherapy Acta Oncol 40 102 104 11321651 10.1080/028418601750071154 1:STN:280:DC%2BD3M3jvVaksg%3D%3D Shioyama Y, Yakeishi Y, Watanabe T, et al.: Long-term control for a retroperitoneal metastasis of malignant gastrointestinal stromal tumor after chemoradiotherapy and immunotherapy. Acta Oncol 2001, 40:102–104.